Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;5(3):283-288.
doi: 10.3892/mco.2016.940. Epub 2016 Jun 24.

Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer

Makiko Ikagawa  1 , Michio Kimura  2 , Mina Iwai  2 , Eiseki Usami  2 , Tomoaki Yoshimura  2 , Kimio Yasuda  1
Affiliations

Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer

Makiko Ikagawa et al. Mol Clin Oncol. 2016 Sep.

Abstract

The aim of this retrospective study was to investigate the safety of S-1 as second-line therapy and to evaluate the association between neutropenia occurring during first-line gemcitabine (GEM) therapy and survival for advanced or recurrent pancreatic cancer (APC). Between January, 2010 and December, 2014, 123 APC patients received chemotherapy at the Ogaki Municipal Hospital (Ogaki, Japan). Of those, 37 received GEM as first-line and S-1 as a second-line therapy (GEM→S-1 group). A further 60 patients received GEM as first-line therapy, but did not receive second-line therapy (GEM group). The median overall survival in the GEM→S-1 (n=37) and GEM (n=60) groups was 323 days [95% confidence interval (CI): 138-218.9 days] and 172 days (95% CI: 105-184.4 days), respectively (P=0.0004). The median overall survival in the mild (grade ≤2; n=63) and severe (grade ≥3; n=34) neutropenia groups was 178 days (95% CI: 182-275 days) and 330 days (95% CI: 297-514 days), respectively (log-rank test, P=0.0023). The severe non-haematological toxicities associated with S-1 as second-line therapy were nausea (2.7%) and hand-foot syndrome (2.7%). Second-line S-1 treatment was discontinued due to adverse events in 5.4% (2/37) of the cases. In conclusion, neutropenia occurring during GEM therapy administered as first-line treatment to APC patients was strongly associated with a better prognosis. S-1 therapy as second-line treatment was associated with a low incidence of severe adverse events and the patients were able to successfully continue treatment.

Keywords: S-1; adherence; gemcitabine; neutropenia; pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves of overall survival in the gemcitabine (GEM)→S-1 and GEM groups. Solid line, GEM→S-1group. Median survival time (MST), 323 (64–1514) days. Dotted line, GEM group. MST, 172 (33–918) days.
Figure 2.
Figure 2.
Kaplan-Meier survival curves showing the highest grade of neutropenia following first-line therapy with gemcitabine (GEM). Solid line, patients who had severe neutropenia (grade ≥3) during treatment with GEM. Median survival time (MST), 330 (47–1514) days. Dotted line, patients who had mild neutropenia (grade ≤2) during treatment with GEM. MST, 178 (33–918) days.
See this image and copyright information in PMC

References

    1. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T. Research Group of Population-Based Cancer Registries of Japan: Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: A chronological and international comparative study. Jpn J Clin Oncol. 2011;41:40–51. doi: 10.1093/jjco/hyq167. - DOI - PubMed
    1. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–2413. - PubMed
    1. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640–1648. doi: 10.1200/JCO.2012.43.3680. - DOI - PubMed
    1. Hatori M, Tsuji D, Taku K, Daimon T, Kamezato M, Ikeda M, Makuta R, Hayashi H, Inoue K, Itoh K. Prognostic factors in patients with unresectable pancreatic cancer treated with gemcitabine: a retrospective analysis. Jpn J Pharm Health Care Sci. 2014;40:734–741. doi: 10.5649/jjphcs.40.734. - DOI
    1. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45:1950–1958. doi: 10.1016/j.ejca.2009.01.023. - DOI - PubMed